AIM Public Comment for the May 2025 Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting
AIM submitted public comment for the May 22, 2025, meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC).
AIM submitted public comment for the May 22, 2025, meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC).
AIM submitted public comment for the April 15-16, 2025, meeting of the Advisory Committee on Immunization Practices (ACIP).
AIM's testimony to the House Subcommittee on Labor, HHS, Education, and Related Agencies regarding funding for the Section 317 Immunization Program.
AIM released a statement on the Biden Administration’s Bridge Access Program For COVID-19 Vaccines and Treatments to Maintain Access to COVID-19 Care for the Uninsured.
AIM recognizes that the availability of influenza vaccine and other factors outside the immunization program’s control will vary season to season, but offers…
Association of Immunization Managers (AIM) Executive Director Claire Hannan has issued this statement regarding recent comments made across public health regarding COVID19 vaccine development and forthcoming distribution.
AIM is urging Congress to invest in three key areas to strengthen the nation’s immunization infrastructure to prepare for mass vaccination against COVID-19.
The effectiveness of vaccines depends on proper storage and handling from manufacture to administration.
AIM statement on the Senate’s Proposed Elimination of Prevention and Public Health Fund Would Cripple Immunization Efforts Nationwide
AIM offers recommendations and guidance to awardees to distribute VFC seasonal influenza vaccine to provider offices early in the influenza season and to reduce missed opportunities for VFC providers to vaccinate against influenza.